December 2018 - Glycostem is proud to be commercial partner in the Marie Curie “Mature-NK” programme. The funding for the CAR-NK technology will be well invested.

Glycostem Therapeutics B.V. (Glycostem), a clinical stage company focusing on the immuno oncology applications of safe, off-the-shelf and cost-effective NK- and CAR-NK-cells, announces participation in MATURE-NK with 12 other European academic institutions and companies, funded with 3.51 million Euro by the EU Horizon 2020.

Over the next 4 years Glycostem in, as part of the consortium led by Prof Ulrike Köhl from Leipzig, work on developing novel methods to manufacture tumour reactive NK cells. The consortium consists of nine academic centres covering basic and translational research, as well as 3 leading biotech companies (Innate Pharma, Miltenyi and Glycostem) and Fraunhofer IZI as a world leading research institute. The objective is to educate top level selected PhD candidates not only in science, but also have a strong focus on business and management activities as well as basic and advanced knowledge in strategies around intellectual property.

Jan Spanholtz, PhD, Glycostem’s CSO, says, “I like this highly inspiring network activities, stimulating development of new collaborations. As a company we have access to the best educated scientists and contribute to their PhD training with business and IP courses, allowing them to generate a hot profile for excellent career opportunities in biotech business.”

Prof. Ulrike Köhl, PhD, MD, at University clinical centre Leipzig and Hannover Medical School as well as director of Fraunhofer IZI in Leipzig, states: “I am very excited, that we have the chance to continue educating highly talented PhD candidates in the field of NK cell immunotherapy. I am proud to have the top academic NK cell researchers and most important NK cell related biotech companies of Europe in one consortium, which generates a great momentum to develop new NK cell products for the coming years, to help cancer patients.”

List of partner insistuations:

• Hannover Medical School, Hannover, Germany
• University Hospital Oslo, Oslo, Norway
• University Basel, Basel, Switzerland
• University Hospital Genoa, Genoa, Italy
• Institut Pasteur, Paris, France
• University Heidelberg – Faculty Mannheim, Mannheim, Germany
• Universitat Pompeu Fabra, Barcelona, Spain
• Hebrew University Jerusalem, Jerusalem, Israel
• Medical University of Vienna, Max F. Perutz Laboratories, Vienna, Austria
• Innate Pharma SA, Marseille, France
• Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany
• Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany